Methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDOMe) is a synthetic oleanolic acid derivative that displays antitumorigenic and anti-inflammatory activities, and we have previously reported that this agent potently activates the intrinsic apoptotic pathway in leukemia cells. In this study, we demonstrate that mitochondrial dysfunction induced by CDDO-Me is mediated by direct permeabilization of the inner mitochondrial membrane, which results in the rapid depletion of mitochondrial glutathione (GSXm), loss of cardiolipin, and inhibition of mitochondrial respiration. More importantly, we demonstrate that in addition to activating the intrinsic apoptotic pathway, the mitochondrial effects of CDDO-Me may mediate its anti-inflammatory activity by modulating the generation of superoxide anion (O 2 . ). It is noteworthy that CDDO-Me did not increase the generation of O 2 . , and pretreatment of leukemia cells with CDDO-Me prevented the increase of this reactive oxygen species elicited by inhibition of complex I or III in the absence of de novo protein synthesis. CDDO-Me, but not other inhibitors of respiration, induced a time-and dose-dependent, cyclosporin A-independent permeability transition (PT) of isolated mitochondria that was sensitive to sulfhydryl antioxidants but not to EDTA. PT induced by CDDO-Me and Ca 2ϩ was accompanied by loss of GSXm, suggesting that the increased permeability of the inner mitochondrial membrane facilitates the loss of this antioxidant. Finally, transmission electron microscopy revealed that CDDO-Me rapidly induced caspase-independent mitochondrial swelling and loss of inner membrane structure before the release of cytochrome c. Taken together, our results indicate that CDDO-Me is a novel mitochondriotoxic agent that induces apoptosis and inhibits mitochondrial electron transport via perturbations in inner mitochondrial membrane integrity.
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2-Cyano-3,12-dioxooleana-1,9-diene-28-oic acid (CDDO) is a synthetic triterpenoid that displays potent anti-inflammatory and antitumorigenic activities in vitro and in vivo (Suh et al., 1999; Lapillonne et al., 2003; Konopleva et al., 2004) . CDDO and its more potent methyl ester derivative, methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me), induce apoptosis and differentiation in leukemia cells in culture, and we have demonstrated that apoptosis induced by these agents is initiated by the intrinsic apoptotic pathway possibly through direct perturbation of mitochondrial homeostasis (Konopleva et al., 2002 (Konopleva et al., , 2004 . As an anti-inflammatory agent, CDDO has been shown to potently prevent ileitis induced by Toxoplasma gondii infection (Minns et al., 2004) and to prevent activation of the proinflammatory transcription factor NFB by TNF␣ and interleukin 1␤ (Stadheim et al., 2002; Elliott et al., 2003) . It is noteworthy that several antioxidants that display anti-inflammatory activity also inhibit NFB signaling (Zhang and Frei, 2001; Rota et al., 2002; Sola et al., 2005) , and a recent report linked an antioxidant activity of CDDO and its derivatives to increased expression of phase II response enzymes (heme oxygenase 1, superoxide dismutase, etc.) via activation of nrf2 signaling, perhaps suggesting a plausible mechanism for the anti-inflammatory properties of these agents (Dinkova-Kostova et al., 2005) . However, the precise anti-inflammatory and antitumorigenic mechanisms of action of CDDO and CDDO-Me remain elusive. CDDO will soon enter phase I clinical trials for the therapy of hematological and solid malignancies, and understanding the molecular pharmacology of these promising compounds is of utmost importance to maximize their clinical utility.
The mitochondria are central regulators of cellular metabolism, because in addition to carrying out oxidative phosphorylation (ATP synthesis), these organelles harbor enzymes for the oxidation of fatty acids, the synthesis of steroid hormones, and the recycling of carbon skeletons for nucleic acid and protein synthesis (Sherratt, 1991 ). An inevitable consequence of mitochondrial electron transport is the generation of superoxide anion (O 2 . ) that results when an electron "leaks" from the electron transport chain and reacts with molecular oxygen (Andreyev et al., 2005) . O 2 . is a highly reactive oxygen species (ROS) that can directly damage lipids and proteins and is a precursor to other ROS like H 2 O 2 . Curiously however, in addition to being an essential component of inflammation (Trenam et al., 1991; Fubini and Hubbard, 2003) , mitochondrial-derived ROS have also been shown to be necessary for the activation of a variety of transcription factors, including NFB and activating protein 1 (Kohler et al., 1999; Maziere et al., 1999) , and in fact, impairment of mitochondrial electron transport or increased antioxidant capacity have been shown to inhibit the activation of NFB by a variety of stimuli (Josse et al., 1998; Azevedo-Martins et al., 2003; Woo et al., 2004) . These findings suggest that agents that affect mitochondrial electron transport could also have anti-inflammatory activity by modulating O 2 . generation and NFB signaling.
The mitochondria also regulate cell death through the release of proapoptotic proteins from their intermembrane space into the cytosol (Green and Reed, 1998; Festjens et al., 2004) . The release of these death-promoting proteins can be mediated by an increase in permeability of the outer mitochondrial membrane that can be induced by proapoptotic bcl-2 family members (Sharpe et al., 2004) . On the other hand, an increase in permeability of the inner mitochondrial membrane to solutes Ͻ1.5 kDa results in large-amplitude swelling of the mitochondria, rupture of the outer mitochondrial membrane, and release of proapoptotic proteins. This phenomenon termed the mitochondrial permeability transition (mPT) is induced by a variety of chemicals, including Ca 2ϩ , arsenicals, atractyloside, diamide, and other oxidative stressors that activate mitochondrial conductance pores. mPT can be prevented by cyclosporine A (CsA), an inhibitor of PT pore conductance, and interestingly, a recent report demonstrated that cholesterol modulated mPT by altering inner membrane fluidity . In light of the well documented ability of cholesterol to alter membrane fluidity (Kusumi et al., 1986; Subczynski et al., 1991) and the direct mitochondriotoxic effects of the steroids dexamethasone and 7-ketocholesterol (Petit et al., 1995; Miguet et al., 2001) , we questioned whether a molecule like CDDO-Me that is structurally similar to cholesterol may similarly affect mitochondrial membrane fluidity and modulate mPT.
Herein, we report the ability of CDDO-Me to directly induce CsA-insensitive mPT independently of Ca 2ϩ , which results in rapid inhibition of electron transport and is characterized by the selective loss of mitochondrial glutathione. Our results demonstrate that the mitochondrial perturbations induced by CDDO-Me occur before the onset of apoptosis and are independent of caspase activation. Most important, we present evidence demonstrating that CDDO-Me is a putative antioxidant by its ability to inhibit the generation of O 2 .
independent of protein synthesis. This is the first report to identify the precise mitochondriotoxic effects of this novel triterpenoid.
Materials and Methods
Cell Lines, Chemicals, and Biochemicals. U937, HL60, Jurkat T, HCT116, HCT116 BaxϪ/Ϫ, and OCI-AML3 cells were maintained in RPMI medium supplemented with 10% fetal calf serum, 1% glutamine, and 100 units/ml penicillin in a 37°C incubator containing 5% CO 2 . Before every experiment, cell viability was quantitated by trypan blue exclusion using a hemocytometer and found to be Ͼ90%. All experiments unless stated otherwise were carried out at a cell density of 300,000 cells/ml. CDDO-Me was kindly provided by Dr. Edward Sausville (National Cancer Institute, Bethesda, MD) under the Rapid Access to Intervention Development program. TMRM, dihydroethidine, and COXIV antibody were obtained from Invitrogen (Carlsbad, CA). z-VAD-fmk was purchased from Alexis Biochemicals (San Diego, CA). Hemeoxigenase-1 (HO-1), cytochrome c, and Bax antibodies were purchased from BD Biosciences (San Jose, CA), and ␣-tubulin and apoptosis-inducing factor (AIF) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody against caspase 3 was purchased from Cell Signaling Technology (Beverly, MA). All other chemicals used were of the highest purity available.
Synthesis of BB-CDDO. A mixture of CDDO (40 mg, 0.081 mmol), (ϩ)-biotinyl-3,6,9-trioxaundecanediamine (67 mg, 0.16 mmol), 2Ј,3Ј-dideoxycytidine (33 mg, 0.16 mmol), and catalytic amount of 4-dimethylaminopyridine in anhydrous CH 2 Cl 2 (3 ml) was stirred at room temperature for 2 days under Argon. After the solvent was removed, the residue was purified by preparative thinlayer chromatography [CH 2 Cl 2 -MeOH (9:1)] to afford starting material CDDO (24 mg) and BB-CDDO (23 mg, 79% based on consumed CDDO) as an amorphous solid. IR (neat): 3317, 2925, 2860, 1691, 1650, 1530, 1454, 1098 : ␦ 199.69, 196.91, 177.71, 173.65, 169.20, 166.22, 164.33, 124.25, 114.80, 114.76, 70.73, 70.69, 70.41, 70.37, 70.33, 70.28, 62.11, 60.54, 55.93, 49.81, 48.01, 46.82, 46.23, 45.32, 42.91, 42.47, 40.83, 39.58, 39.44, 36.41, 36.17, 34.96, 34.25, 33.63, 32.06, 32.00, 30.94, 28.49, 28.38, 28.12, 27.25, 26.86, 25.85, 25.07, 23.44, 23.12, 22.06, 21.87, 18.56 (Zhang et al., 2000) colon carcinoma cells were grown in T-175 flasks in RPMI medium supplemented with 10% FBS until 60 to 70% confluent. Cells were then collected in ice-cold PBS by scraping using a rubber policeman. Cell pellets were collected by centrifugation and washed in 10 volumes of ice-cold PBS. Cells were resuspended in 10 volumes of ice-cold CEI buffer (20 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , and 1 mM EDTA) and incubated on ice for 10 min. The swollen cell suspension was homogenized by forcefully passing through a 24 G needle six to eight times. One volume of ice-cold CEII buffer (CEI buffer supplemented with 170 mM sucrose and 440 mM mannitol) was added to the cell suspension and gently mixed by inversion followed by centrifugation at 800 rpm for 5 min to collect nuclei and unbroken cells. The supernatant was then centrifuged at 3500 rpm for 10 min, and the pellet was washed twice in ice-cold CEII buffer. The mitochondrial pellet was resuspended in 500 l of M buffer (125 mM KCl, 20 mM HEPES, 10 mM Tris-Cl, and 2 mM KPO 4, pH 7.2) and maintained on ice. Protein was quantitated from 5 l of a 1:5 dilution using the bicinchoninic acid method. The purity of the mitochondrial preparations was routinely assessed by Western blot. Fractions were immunoblotted with COXIV and glyceraldehyde-3-phosphate dehydrogenase to determine the presence of mitochondrial and cytosolic components, respectively. Using the above methodology, cross-contamination of cytosolic and mitochondrial fractions was not observed. Mitochondria were then resuspended in M buffer supplemented with 10 mM succinate and 0.5 M rotenone or M buffer alone (for de-energized experiments) at 0.8 mg/ml protein and equilibrated at room temperature for 2 min before the addition of test compounds. The concentration of DMSO in the solution did not exceed 0.2%. Light scatter at 540 nm was monitored using a Fluostar Optima microplate reader (BMG Labtech, Durham, NC).
Measurement of Phosphatidyl Serine Externalization and Mitochondrial Membrane Potential. After appropriate treatments, cells were washed twice in PBS and then resuspended in 100 l of Annexin binding buffer (140 mM NaCl, 10 mM KH 2 PO 4 , and 5 mM CaCl 2 , pH 7.4) containing 25 nM TMRM and 1:100 dilution of Annexin V-FLUOS (Roche Diagnostics, Mannheim, Germany) and incubated at 37°C for 30 min. Cells were then analyzed by flow cytometry in a FACSCalibur flow cytometer (BD Biosciences) using an argon excitation laser at 488 nm.
Measurement of ROS Generation. One hour before the end of appropriate treatments, cells were loaded with dihydroethidine (317 nM), and incubation continued at 37°C. Cells were then harvested by centrifugation and washed twice in PBS, and FL2 fluorescence was examined by flow cytometry. Results presented are means Ϯ S.E. of three independent experiments.
Western Blot Analysis. Cells where harvested by centrifugation, washed twice in PBS, and resuspended in ice-cold lysis buffer (1% Triton X-100, 45 mM KCl, and 10 mM Tris, pH 7.5), supplemented with protease and phosphatase inhibitors; then subjected to SDSpolyacrylamide gel electrophoresis in 10% or 12% polyacrylamide gels followed by protein transfer to a Hybond-P membrane (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and immunoblotting. Signals were detected by a PhosphorImager (Storm 860, version 4.0; GE Healthcare).
Measurement of Cardiolipin Content. After appropriate treatments, cells were harvested by centrifugation, washed once in PBS, and resuspended in PBS containing 10 nM nonyl acridine orange (NAO), a probe that binds with high affinity to reduced but not oxidized cardiolipin (Umansky et al., 2000) . Cells were incubated 37°C for 30 min, and FL1 fluorescence was quantitated by flow cytometry.
Transmission Electron Microscopy. After appropriate treatments samples were fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, for 1 h. After fixation, the samples were washed and treated with 0.1% Millipore-filtered cacodylate buffered tannic acid, postfixed with 1% buffered osmium tetroxide for 30 min, and stained en bloc with 1% Millipore filtered uranyl acetate (Millipore Corporation, Billerica, MA). The samples were dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in Spurr's low viscosity medium. The samples were polymerized in a 70°C oven for 2 days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL USA Inc., Peabody MA) at an accelerating voltage of 80 kV. Digital images were obtained using AMT Imaging System (Advanced Microscopy Techniques Corp., Danvers, MA).
Measurement of Lactate Generation. Cells were collected by centrifugation and the supernatant was analyzed for lactate content using an Accutrend lactate analyzer with a linear range of standard lactate concentrations according to the procedures recommended by the manufacturer (Roche).
Biochemical Assay for GSX. In brief, 5 ϫ 10 6 to 1.5 ϫ 10 7 cells were cultured under normal conditions and treated as indicated. Cells were then collected, washed twice in ice-cold PBS, and resuspended in 55 l of 10 mM HCl. After incubation on ice for 5 min, insoluble cellular debris was spun down, and protein concentration was measured from 5 l of supernatant using a commercially available bicinchoninic acid protein kit (Pierce Biotechnology, Rockford, IL). The remaining supernatant was mixed with 50 l of 10% metaphosphoric acid and incubated at room temperature for 5 min. Proteins were precipitated at 12,000g for 5 min, and the supernatant was neutralized by the addition of 10 l of a 4 M triethanolamine solution. Twenty-five microliters of supernatant were mixed with 75 l of buffer G [100 mM KPO 4 , 10 mM EDTA, 240 M NADPH, 0.3 mg/ml 5,5Ј-dithiobis(2-nitrobenzoic acid), and 1 U/ml glutathione reductase, pH 7.5], and absorbance was read at 405 nm on a plate reader after 10-min incubation at room temperature, and GSX concentrations were calculated from a standard curve of GSSG. Results are expressed as picomoles of GSX per microgram of protein. For measurement of GSX in the mitochondrial fraction, mitochondria were isolated from 1.5 ϫ 10 7 cells by density centrifugation using a commercially available kit (Pierce) and washed twice in isolation buffer (75 mM KCl, 10 mM EDTA, and 250 mM sucrose, pH 7.4), and mitochondrial pellets were resuspended in 50 l of 10 mM HCl. Protein concentrations and total GSX content were measured as described above.
Measurement of Oxygen Consumption. Cells were resuspended in 1 ml of fresh warm medium pre-equilibrated with 21% oxygen and placed in the sealed respiration chamber equipped with a thermostat control, a microstirring device, and a Clark-type oxygen electrode disc (Oxytherm; Hansatech Instrument, Cambridge, UK). The oxygen content in the cell suspension medium and oxygen consumption rate were constantly monitored, and the signals were integrated using the software supplied by the manufacturer.
Quantitation of Caspase 9 Activity. After treatments, cells were collected by centrifugation and washed in 10 volumes of ice-cold PBS. Cells were then resuspended in 10 volumes of ice-cold CEI buffer (20 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , and 1 mM EDTA) and incubated on ice for 10 min. The swollen cell suspension was homogenized by forcefully passing through a 24 G needle six to eight times and centrifuged at 10,000g for 10 min to collect cytosolic extracts. Ten micrograms of cytosolic extract protein were incubated with 25 M z-LEHD-rhodamine 110 conjugate (Molecular Probes), and fluorescence emission at 520 nm (excitation at 485 nm) was quantitated using a Fluostar Optima microplate reader (BMG Labtech). it has been reported that caspases are indispensable for loss of ⌬⌿M during apoptosis induced by staurosporine, UV radiation, or TNF␣/cycloheximide (Ricci et al., 2004) , we investigated whether pharmacological inhibition of caspases would prevent the loss of ⌬⌿M induced by CDDO-Me in U937 cells. For these experiments, we used the potentiometric probe TMRM, a positively charged lipophilic cation that accumulates in metabolically active mitochondria. As shown in Fig. 1A , treatment of U937 cells with 300 nM CDDO-Me for 3 h resulted in a significant loss (p Ͻ 0.0005) of cells positive for TMRM fluorescence, and this effect was not sensitive to pharmacological inhibition of caspases using the pancaspase inhibitor z-VAD-fmk (50 M). In contrast, z-VAD-fmk abrogated the appearance of the caspase-dependent cleavage products of caspase 3 in U937 cells treated with CDDO-Me (Fig. 1B) . Cardiolipin is the most abundant mitochondrial phospholipid and is responsible for maintaining the impermeability of the inner mitochondrial membrane (Sherratt, 1991) . To investigate whether CDDO-Me induced perturbations in the cardiolipin content, U937 cells were treated with 300 nM CDDO-Me for 3 h, and the fluorescence of the cardiolipin-specific probe NAO was assessed by flow cytometry as described under Materials and Methods. Our results show that CDDO-Me induced a z-VAD-fmk-insensitive 26% loss (p Ͻ 0.005) of cells stained by NAO, suggesting that the rapid loss of ⌬⌿M is associated with a loss of mitochondrial mass that is independent of caspase activity (Fig. 1C) . Taken together, these findings demonstrate that in contrast to staurosporine, UV radiation, or TNF␣/cycloheximide, CDDO-Me induces caspase-independent damage to the mitochondria.
Results

CDDO-Me Induces
The Mitochondriotoxicity of CDDO-Me Is Not Dependent on Bax. Because we have reported that CDDO-Me induced the redistribution of Bax from the cytosolic to the mitochondrial compartment of U937 cells (Konopleva et al., 2002) , we investigated whether the observed changes in ⌬⌿M and cardiolipin content were a result of this effect. As our Western blot analysis demonstrates, the cytosolic-mitochondrial translocation of Bax does not occur until 6 h after treatment of U937 cells with 300 nM CDDO-Me (Fig. 1D) , whereas significant loss in ⌬⌿M and cardiolipin content occur at 3 h (Fig. 1, A and C) , suggesting that the observed perturbations in mitochondrial homeostasis are independent of this phenomenon. It is noteworthy that loss of mitochondrial cytochrome c is evident as early as 3 h after treatment with CDDO-Me, and maximum release of this proapoptotic protein, as well as of AIF, coincided with the mitochondrial translocation of Bax, suggesting that Bax facilitates outer membrane permeability but does not initiate this event. Similar observations were made by immunohistochemistry (data not shown). Finally, to further clarify the role of Bax in CDDO-Me-induced apoptosis, we also investigated whether CDDO-Me could induce mitochondrial dysfunction in the HCT116 BaxϪ/Ϫ cell line (Zhang et al., 2000) and in the Baxdeficient Jurkat T cell line, which lacks detectable Bax expression because of a frameshift mutation in the coding region of the Bax gene. As shown in Fig. 1E , CDDO-Me can rapidly induce loss of ⌬⌿M and cardiolipin in Bax-deficient cells, suggesting that mitochondrial translocation of this proapoptotic protein is not required to mediate the observed mitochondriotoxicity.
The Mitochondriotoxic Effects of CDDO-Me Are Associated with a Rapid and Selective Depletion of Mitochondrial Glutathione. Because cholesterol deposition on the mitochondria leads to severe depletion of mitochondrial glutathione (GSXm) via perturbations in membrane fluidity Fernandez-Checa, 2003) , we investigated whether the structurally similar CDDO-Me (Fig. 2E) would also lead to GSXm depletion in leukemia cell mitochondria. CDDO-Me produced a striking dose-and timedependent depletion of GSXm in U937 cells, displaying EC 50 values of 180 nM and producing a 67% loss after 180 min without any marked effects on whole-cell glutathione (GSXwc) content (Fig. 2, A and B) . Likewise, 1 M CDDO-Me induced a 45% loss of GSXm in OCI-AML3 cells after 180 min (p Ͻ 0.01; Fig. 2C ). It is noteworthy that the lower sensitivity of OCI-AML3 cells to the GSXm-depleting effects of CDDO-Me mirrors the cells' decreased susceptibility to the cytotoxicity of this agent (data not shown). In light of these results, we investigated the subcellular localization of a biotinylated derivative of CDDO, BB-CDDO, by fluorescence microscopy to determine whether this compound would demonstrate discrete cytoplasmic localization. For these experiments, we treated U937 cells with 10 M BB-CDDO for 4 h, followed by staining with the mitochondrial-specific probe MitoTracker Green (MTG). After fixation and permeabilization, the cells were stained with Texas Red-conjugated streptavidin (TR-S) and analyzed under a fluorescent microscope. As shown in Fig. 2D , localization of BB-CDDO with TR-S resulted in a discrete pattern of cytoplasmic staining that mostly colocalized with the MTG stain. Together, these results suggest that CDDO-Me, like cholesterol, induces perturbations in the integrity of the mitochondrial membrane leading to selective loss of GSXm.
CDDO-Me Rapidly Inhibits Oxygen Consumption and Mitochondrial Electron Transport:
The True Antioxidant Nature of CDDO-Me. Because cholesterol deposition in membranes has been reported to decrease oxygen permeability (Subczynski et al., 1991) we investigated whether CDDO-Me would affect oxygen consumption in U937 cells. CDDO-Me led to a rapid time-dependent inhibition of cellular oxygen consumption in U937 cells, and similar results were obtained in OCI-AML3 cells (Fig. 3, A and B) . Because the generation of O 2
. is an inevitable consequence of oxidative phosphorylation, we examined whether CDDO-Me modulated the levels of this ROS in U937 cells. For these experiments, we treated U937 cells with 300 nM CDDO-Me alone or in combination with the protein synthesis inhibitor cycloheximide (CHX), because it has been reported that CDDO and its derivatives increase the expression of the antioxidant enzyme HO-1 (Dinkova- Kostova et al., 2005) . HO-1 catalyzes the breakdown of heme into carbon monoxide, iron, and the endogenous antioxidant biliverdin, and up-regulated expression of this enzyme results in increased capacity to scavenge ROS (Schaaf et al., 2002) and may mask possible O 2 . -generating effects of CDDO-Me. It was observed that CDDO-Me (300 nM) increased the expression of HO-1 in U937 cells within 3 h of treatment, and 3.5 M CHX completely prevented this effect (Fig. 3C ). Under these same conditions, treatment of U937 cells with CDDO-Me alone resulted in decreased levels of O 2 . , and in fact, CDDO-Me prevented the moderate increase in this ROS induced by CHX treatment (Fig. 3D) . We then investigated whether CDDO-Me would prevent the increase in O 2 . induced by blocking complex I with 2 M rotenone. As illustrated in Fig. 4A , CDDO-Me in the presence of CHX completely prevented the generation of O 2 . induced by rotenone in U937
CDDO-Me Targets Mitochondrial Membrane Permeability Fig. 1 . CDDO-Me induces direct caspase-independent damage to the mitochondria of U937 cells. A, U937 cells were treated with 300 nM CDDO-Me for 3 h alone or in the presence of the pancaspase inhibitor z-VAD-fmk (50 M; 30 min pretreatment), and ⌬⌿M was measured by flow cytometry as described under Materials and Methods. B, U937 cells were treated with 300 nM CDDO-Me for 6 h alone or in the presence of the pancaspase inhibitor z-VAD-fmk, and active caspase 3 was examined by Western blot. Arrows indicate the uncleaved (35 kDa) and caspase-cleaved fragments (19 and 17 kDa) of caspase 3. C, U937 cells were treated as in A, and cardiolipin content was quantitated by flow cytometry as described under Materials and Methods. D, U937 cells were treated with 300 nM CDDO-Me for 2, 3, and 6 h, and cytochrome c, AIF, Bax, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; cytosolic loading control), and COXIV (mitochondrial loading control) were evaluated by Western blot in cytosolic (C) and mitochondrial (M) extracts as described under Materials and Methods. E, HCT116, HCT116 BaxϪ/Ϫ, and Jurkat T cells were treated with CDDO-Me (500 nM for 5 h), and ⌬⌿M and cardiolipin content were quantitated by flow cytometry. ‫,ء‬ p Ͻ 0.005 from DMSO; ‫,ءء‬ p Ͼ 0.05 from CDDO-Me. , and 300 nM CDDO-Me for 3 h, and GSXm and GSXwc were quantitated biochemically as described under Materials and Methods. B, U937 cells were treated with 300 nM CDDO-Me for 60, 120, and 180 min, and GSXm and GSXwc were quantitated as above. C, OCI-AML3 cells were treated with 500 and 1000 nM CDDO-Me for 3 h, and GSXm and GSXwc were quantitated as above. D, U937 cells were treated with 10 M BB-CDDO (C28-biotinylated CDDO) for 4 h and stained with the mitochondrial specific dye MitoTracker Green (Molecular Probes) for 30 min. Cells were then stained with TR-S after fixation/permeabilization and analyzed by fluorescence microscopy. E, the structures of BB-CDDO (top) and CDDO-Me (bottom). ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.005.
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CDDO-Me actually induced a mild increase in O 2 . (Fig. 4C ).
Under these conditions, CHX did not significantly (p Ͼ 0.05) prevent the increase in ROS induced by rotenone. These results suggest that CDDO-Me blocks electron transport upstream of complex I. Because blocking the entry of electrons from pyruvate into complex I would lead to an increase in extracellular lactate levels, we investigated the levels of this metabolite in the culture medium of U937 and OCI-AML3 cells treated with CDDO-Me. We found that treatment with CDDO-Me for 20 h increased the levels of lactate in the medium of U937 (3.1-fold; p Ͻ 0.005) and OCI-AML3 (1.6-fold; p Ͻ 0.05) cells, further supporting the notion that this agent prevents the entry of electrons from pyruvate onto complex I (Fig. 4, D and E) . Taken together, the above data demonstrate that CDDO-Me is a putative antioxidant via its ability to directly inhibit the generation of O 2 . , presumably by preventing electron transport and/or inhibiting oxygen consumption. CDDO-Me Induces CsA-Independent Permeability Transition in Isolated Mitochondria. To further investigate the mitochondriotoxic effects of CDDO-Me we determined whether this agent would induce mitochondrial swelling in mitochondria isolated from HCT116 cells. As the results in Fig. 5A illustrate, CDDO-Me induced a time-and dose-dependent decrease in the light scattering at 540 nm of energized HCT116 mitochondrial suspensions, suggesting that this agent induces the permeability transition of mitochondria (mPT). It is noteworthy that 4 M CDDO-Me induced a very large decrease in absorbance (ϳ0.5) comparable with that induced by 200 M Ca 2ϩ , suggestive of complete disintegration of the mitochondrial membrane. Similar observations were made in de-energized mitochondrial suspensions (data not shown). It is important to mention that the amount of CDDO-Me per milligram of mitochondrial protein used in these experiments is comparable with the amount of CDDO-Me used per milligram of U937 protein in our cell culture experiments (2-8 nmol/mg protein). Consistent with our observation that CDDO-Me can induce mitochondrial dysfunction in HCT116 BaxϪ/Ϫ cells, mitochondria isolated from these cells were similarly susceptible to CDDO-Meinduced mPT (Fig. 5B) , and this supports recent reports demonstrating that HCT116 BaxϪ/Ϫ mitochondria undergo mPT in response to Ca 2ϩ to a similar extent than wild-type HCT116 mitochondria (De Marchi et al., 2004; Campello et al., 2005) . We then questioned whether the permeability transition conductance pore (PTP) mediated the mitochondrial swelling induced by CDDO-Me. Our results demonstrate that pretreatment of the mitochondrial suspensions with 2 M CsA, a classic inhibitor of the permeability transition, did not prevent the large amplitude swelling induced by 4 M CDDO-Me, whereas this treatment completely prevented swelling induced by 200 M Ca 2ϩ (Fig. 5C ). It is noteworthy that the antioxidant DTT completely prevented mPT induced by CDDO-Me, whereas it was ineffective in preventing mitochondrial swelling induced by Ca 2ϩ , suggesting that the ␣,␤-unsaturated ketone moieties of CDDO-Me may mediate its mitochondriotoxic effects (Fig. 5D ). To then investigate whether our observations in isolated mitochondria were relevant in the context of the whole cell, we quantitated the enzymatic activity of caspase 9 in cytosolic extracts of U937 cells treated with CDDO-Me, alone or in combination with DTT, CsA, or rotenone. Consistent with our observations in isolated mitochondria, DTT, but not CsA or rotenone, completely prevented caspase 9 activation induced by CDDO-Me in U937 cells (Fig. 5E ), suggesting that in the context of the whole cell, cytochrome c release with subse- molpharm.aspetjournals.org quent activation of the apoptosome can be initiated by ␣,␤-unsaturated ketone-dependent effects of this agent independently of the PTP. In addition, we confirmed that mPT induced by Ca 2ϩ , but not that induced by CDDO-Me, was sensitive to inhibition by 2 mM EDTA (Fig. 5C) , and similar results were obtained using de-energized mitochondria (data not shown). Under these experimental conditions, inhibition of complex II, III, or IV did not induce mitochondrial swelling indicating that mPT induced by CDDO-Me is not a consequence of impaired electron transport (data not shown). Finally, we investigated whether CDDO-Me could deplete GSXm in isolated mitochondria, and as illustrated in Fig. 5F , both CDDO-Me (4 M) and Ca 2ϩ (200 M) dramatically decreased GSXm in isolated mitochondria. These results suggest that the rapid and selective loss of GSXm induced by CDDO-Me in U937 cells is mediated by the induction of mPT. In conclusion, these experiments demonstrate that CDDO-Me directly induces mPT in isolated mitochondria in a Bax-, PTP-, and Ca 2ϩ -independent manner, suggesting that like cholesterol, this agent induces a generalized perturbation of inner mitochondrial membrane fluidity.
CDDO-Me Induces Rapid Mitochondrial Swelling and Alterations in Inner Mitochondrial Membrane
Structure in U937 Cells. Finally, we used transmission electron microscopy (TEM) to examine the mitochondrial morphology in U937 cells treated with DMSO or 300 nM CDDO-Me for 30, 60, and 180 min (Fig. 6, A-D) . These TEM images demonstrate that CDDO-Me induces dramatic swelling of the mitochondria as early as 30 min after treatment, and this is associated with decreased electron density of the inner membrane and matrix regions without any visible changes in endoplasmic reticulum (ER) structure, plasma membrane topology, or nuclear organization at this time. Most striking is the complete absence of cristae in U937 cells after 180-min treatment with CDDO-Me, accompanied by massive swelling of the ER membrane and early stages of plasma membrane blebbing. These results are consistent with our finding that CDDO-Me induced a rapid loss of cardiolipin (Fig. 1C) and suggest that mPT induced by CDDO-Me is associated with a selective loss of inner mitochondrial membrane mass. It is noteworthy that the pancaspase inhibitor z-VAD-fmk did not prevent changes in mi- tochondrial morphology induced by CDDO-Me after 180 min, although it weakly attenuated membrane blebbing at this time (Fig. 6E) . These images conclusively show that CDDO-Me rapidly targets the inner mitochondrial membrane before caspase activation, plasma membrane alterations, and ER swelling.
Discussion
We have previously demonstrated that CDDO-Me activated the intrinsic apoptotic pathway to induce cell death in leukemia cells (Konopleva et al., 2002) and reported the observation that apoptosis induced by CDDO displayed caspase-dependent and -independent components (Konopleva et al., 2004) . However, the precise nature of the mitochondriotoxicity of these agents had not been elucidated. Because recent reports suggested that mitochondrial dysfunction induced by staurosporine, UV radiation, or TNF␣/ cycloheximide depended on caspase activation (Ricci et al., 2004) , we first examined whether loss of ⌬⌿M induced by CDDO-Me in U937 cells was also sensitive to pharmacological inhibition of caspases using the broad-spectrum caspase inhibitor z-VAD-fmk. It was observed that loss of ⌬⌿M induced by CDDO-Me was unaffected by z-VAD-fmk, even though under these conditions caspase-dependent processing of caspase 3 was abrogated. Because cardiolipin is the most abundant mitochondrial phospholipid and helps maintain the impermeability of the inner mitochondrial membrane, the content of cardiolipin was quantitated by flow cytometry in U937 cells treated with CDDO-Me alone or in combination with z-VAD-fmk. Our experiments demonstrated that CDDO-Me induced a loss of cardiolipin and that this effect was also unaffected by cotreatment with z-VAD-fmk. Finally, we also demonstrated that the release of cytochrome c and the loss of ⌬⌿M occurs before the mitochondrial translocation of Bax in U937 cells, and using Bax-deficient HCT116 and Jurkat T cells, we show that mitochondrial dysfunction induced by CDDO-Me can occur in the absence of this proapoptotic protein. Because cardiolipin is an essential component of the inner mitochondrial membrane, these results suggest that 1) CDDO-Me directly induces perturbations in the composition of the inner mitochondrial membrane, 2) these perturbations may contribute to the loss of ⌬⌿M, and 3) the mitochondrial dysfunction induced by CDDO-Me is independent of Bax and caspase activation.
How is CDDO-Me inducing perturbation in the composition of the inner mitochondrial membrane? One possibility that was investigated was based on published reports demonstrating that cholesterol deposition in the mitochondria leads to loss of GSXm via perturbations in membrane fluidity Fernandez-Checa, 2003) . Because CDDO and CDDO-Me display some structural similarities to cholesterol, we investigated whether CDDO-Me could selectively deplete GSXm in leukemia cells and found that this agent induced a time-and dose-dependent depletion of GSXm lev- , and cells were fixed and processed for TEM analysis as described under Materials and Methods. E, U937 cells were pretreated with 50 M z-VAD-fmk, followed by treatment with 300 nM CDDO-Me for 180 min and processed for TEM analysis as above. Images on left were captured at 10,000ϫ direct magnification (scale bar, 2 m); images on right correspond to 50,000ϫ direct magnification of boxed area (scale bar, 500 nm).
CDDO-Me Targets Mitochondrial Membrane Permeability 1191
at ASPET Journals on April 12, 2017 molpharm.aspetjournals.org els without any appreciable effect in whole cell glutathione levels (GSXwc). To further investigate whether it was possible for CDDO and CDDO-Me to physically interact with the mitochondria, we examined the subcellular localization of a biotinylated derivative of CDDO-Me, BB-CDDO, in U937 cells. It is noteworthy that although CDDO and CDDO-Me have been shown to be ligands for the nuclear receptor peroxisome proliferator-activated receptor ␥ (Chintharlapalli et al., 2005) , our observations suggest that BB-CDDO localizes mainly in the cytoplasm of U937 cells and that its localization partly overlaps with the signal from the mitochondriaspecific dye MTG. These results indicate that, like cholesterol, CDDO-Me selectively depletes GSXm, and together with our observations on the subcellular localization of BB-CDDO, suggest that this synthetic triterpenoid may have an inherent affinity for mitochondrial components.
A consequence of cholesterol deposition in membranes is a decrease in the permeability of oxygen (Subczynski et al., 1991 (Trenam et al., 1991; Kohler et al., 1999; Maziere et al., 1999; Fubini and Hubbard, 2003) . Because perturbations in the permeability of the inner mitochondrial membrane may result in large-amplitude swelling of the mitochondria, rupture of the outer mitochondrial membrane, and release of proapoptotic proteins, we investigated whether CDDO-Me would induce this mPT in isolated mitochondria. Our observations demonstrate that CDDO-Me induced a time-and dose-dependent mPT in isolated mitochondria from human colon cancer HCT116 cells, as well as their Bax-deficient counterpart (HCT116 BaxϪ/Ϫ) cells. It is noteworthy that different from the mPT induced by Ca 2ϩ , mPT induced by CDDO-Me was independent of the PTP and was not sensitive to the Ca 2ϩ chelator EDTA. It is noteworthy that mPT induced by CDDO-Me was sensitive to the sulfhydryl antioxidant DTT, perhaps suggesting that the ␣,␤-unsaturated ketone moieties of CDDO-Me may contribute to the observed permeabilization of the inner mitochondrial membrane. In support of these observations, it was found that DTT, but not CsA or rotenone, prevented the activation of caspase 9 in U937 cells treated with CDDO-Me. These findings are consistent with the notion that CDDO-Me directly induces perturbations in the permeability of the inner mitochondrial membrane, and the increased in permeability is not mediated by the PTP, suggesting a generalized effect on membrane fluidity.
Finally, we investigated cellular and mitochondrial morphology in U937 cells treated with CDDO-Me using TEM. These TEM images showed a striking alteration of mitochondrial shape and inner electron density, suggesting that CDDO-Me induced mitochondrial swelling and disintegration of the inner mitochondrial membrane of leukemia cells. It is important to emphasize that these events occurred very rapidly (30 min), before alterations in plasma membrane topology, ER membrane topology, or nuclear architecture. At longer time points (60 -180 min), the alterations of the mitochondrial inner membrane induced by CDDO-Me were also accompanied by swelling of the ER and plasma membrane blebbing. Although z-VAD-fmk seemed to attenuate plasma membrane blebbing, this agent failed to prevent mitochondrial damage or ER swelling induced by CDDO-Me.
It is important to note that we have previously reported that Bcl-2 overexpression partially protected against the cytotoxicity of CDDO (Konopleva et al., 2002) ; however, our present data suggest that this may be independent of an interaction with Bax, suggesting that Bcl-2 may have a more general role in protecting the integrity of the mitochondria. Indeed, it has been reported that Bcl-2 can regulate mitochondrial swelling independent of Bax translocation by modulating potassium uptake (Eliseev et al., 2002) . In addition, it has been suggested that Bcl-2 may have an important role in regulating mitochondrial energy metabolism and function independent of its antiapoptotic role (Manfredi et al., 2003) , and Murphy et al. (1996) reported that mitochondria isolated from Bcl-2-overexpressing cells had increased Ca 2ϩ uptake capacity and resisted respiratory inhibition in response to Ca 2ϩ overload. Taken together, these reports suggest the possibility that overexpression of Bcl-2 may protect against the mitochondriotoxicity of CDDO-Me via, at least in part, regulating mitochondrial structure and function independent of its association with Bax.
Our investigations have elucidated the mechanism of mitochondriotoxicity of CDDO-Me and have uncovered novel pharmacological activities of this promising chemotherapeutic: first, the inhibition of oxygen consumption and electron transport, which may be a result of perturbations in mitochondrial membrane fluidity; second, the putative antioxidant activity of CDDO-Me resulting from its ability to prevent the generation of O 2 . ; and third, the permeabilization of the inner mitochondrial membrane independent of the PTP. 
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These pharmacological activities have broad clinical applicability. In particular, the antioxidant nature of CDDO-Me places this novel agent in the frontline as a treatment for inflammatory conditions and autoimmune disorders that are modulated by O 2 . and/or NFB such as graft-versus-host disease, rheumatoid arthritis, and inflammatory bowel disease. At the least, because of its inhibition of mitochondrial metabolism, this agent may have the potential to modulate the synthesis of steroids. By limiting the generation of acetylCoA from pyruvate or succinate, it may possess hypolipidemic and cholesterol lowering activities. Finally, we have demonstrated that cell death caused by CDDO-Me is the result of direct induction of mPT. In conclusion, CDDO-Me represents a novel class of mitochondriotoxic agent that directly targets the inner mitochondrial membrane to inhibit respiratory electron flow and induce apoptosis.
